Cargando…

Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction

AIMS: Inflammation is thought to play a role in heart failure (HF) pathophysiology. Neutrophil‐to‐lymphocyte ratio (NLR) is a simple, routinely available measure of inflammation. Its relationship with other inflammatory biomarkers and its association with clinical outcomes in addition to other risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curran, Fraser M., Bhalraam, U, Mohan, Mohapradeep, Singh, Jagdeep S., Anker, Stefan D., Dickstein, Kenneth, Doney, Alexander S., Filippatos, Gerasimos, George, Jacob, Metra, Marco, Ng, Leong L., Palmer, Colin N., Samani, Nilesh J., van Veldhuisen, Dirk J., Voors, Adriaan A., Lang, Chim C., Mordi, Ify R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318449/ https://www.ncbi.nlm.nih.gov/pubmed/33998162 http://dx.doi.org/10.1002/ehf2.13424

Ejemplares similares

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure
por: Pandhi, Paloma, et al.
Publicado: (2021)

A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure
por: Al-Mubarak, Ali A., et al.
Publicado: (2020)

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
por: Mordi, Ify R., et al.
Publicado: (2019)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
por: Cao, Thong H., et al.
Publicado: (2019)

Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure
por: de Koning, Marie-Sophie L. Y., et al.
Publicado: (2023)

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment
por: Nauta, Jan F., et al.
Publicado: (2019)

Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
por: Boorsma, Eva M., et al.
Publicado: (2021)

Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
por: Inciardi, Riccardo M., et al.
Publicado: (2022)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
por: Markousis-Mavrogenis, George, et al.
Publicado: (2021)

Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use
por: van der Wal, Haye H, et al.
Publicado: (2019)

Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes
por: Mordi, Ify R., et al.
Publicado: (2020)

Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure
por: Cao, Thong Huy, et al.
Publicado: (2018)

Impaired High‐Density Lipoprotein Function in Patients With Heart Failure
por: Emmens, Johanna E., et al.
Publicado: (2021)

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors
por: Sama, Iziah E, et al.
Publicado: (2020)

Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2021)

Albuminuria as a marker of systemic congestion in patients with heart failure
por: Boorsma, Eva M, et al.
Publicado: (2022)

Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence
por: Bracun, Valentina, et al.
Publicado: (2022)

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
por: Singh, Jagdeep S. S., et al.
Publicado: (2016)

Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention
por: Mohan, Mohapradeep, et al.
Publicado: (2021)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
por: Metra, Marco, et al.
Publicado: (2010)

Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2020)

Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire
por: Ravera, Alice, et al.
Publicado: (2021)

A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial
por: Mohan, Mohapradeep, et al.
Publicado: (2019)

Precision Medicine and Adverse Drug Reactions Related to Cardiovascular Drugs †
por: Noyes, James D., et al.
Publicado: (2021)

Clinical implications of low estimated protein intake in patients with heart failure
por: Streng, Koen W., et al.
Publicado: (2022)

Pathophysiological pathways in patients with heart failure and atrial fibrillation( )
por: Santema, Bernadet T, et al.
Publicado: (2021)

Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure
por: Nath, Mintu, et al.
Publicado: (2022)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Genetic risk and atrial fibrillation in patients with heart failure
por: Kloosterman, Mariëlle, et al.
Publicado: (2020)

Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial
por: Mordi, Natalie A., et al.
Publicado: (2020)

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2014)

The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach
por: Hoes, Martijn F., et al.
Publicado: (2019)

Inflammation as a therapeutic target in heart failure with preserved ejection fraction
por: Peh, Zhen Hui, et al.
Publicado: (2023)

A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure
por: Sama, Iziah E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mt6gicvladgodt0vlt03g9le4s